News|Videos|June 19, 2024
Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab
This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.
Advertisement
Episodes in this series
Advertisement
Related to this article
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Navigation Boosts Cascade Genetic Testing in Relatives of BRCA Carriers
2
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
3
Daily Symptom Shifts Linked to Quality of Life in Metastatic Breast Cancer
4
Multidisciplinary Support for Patients with Metastatic Triple-Negative Breast Cancer
5